AZN Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
49 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- 16.42
- PEG ratio
- 1.45
- P/B
- 5.23
- P/S (TTM)
- 4.32
- EV/EBITDA
- 14.29
Profitability & growth
- ROE (TTM)
- 22.0%
- Operating margin
- 23.5%
- Revenue growth YoY
- 6.4%
- Dividend yield
- 1.9%
- Beta
- 0.23
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About AstraZeneca PLC
Company profileAstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 1 FRANCIS CRICK AVENUE, CAMBRIDGE, UNITED KINGDOM
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
